Deep Clinical-Stage Pipeline in Areas of Unmet Need
Targacept’s extensive portfolio of NNR Therapeutics represents multiple opportunities for first-in-class new treatment options for patients.
We leverage more than two decades of scientific focus on NNRs to develop innovative, small molecule product candidates to treat nervous system diseases and disorders. NNRs are a unique class of proteins that function as a sort of “volume knob” to regulate vital biological functions. Our NNR Therapeutics are designed to selectively modulate the activity of specific NNRs considered relevant to particular disease states, while limiting adverse side effects. We work both independently and with academic and industry collaborators to seek breakthrough treatment options for patients.
1 Evaluation of potential Phase 2 development of TC-5619 in this indication ongoing
2 Expected to initiate in 1H14